Innovation Week: Gene Therapy, Psychedelics, Iris Scans

Editorial digest April 19, 2026
Last updated : 08:19

Three stories from the week, three versions of what "innovation" now means. One honours twenty-five years of patient science. One bypasses the queue with a presidential signature. One asks you to hand over your eyeballs to prove you are real. Take your pick.

Why does a gene therapy prize feel like the odd story out?

The so-called Oscar of science landed this week on the least fashionable kind of innovation: the slow one. Molecular biologist Jean Bennett, ophthalmologist Albert Maguire and physician Katherine High were awarded the $3m Breakthrough Prize for life sciences for developing Luxturna, the first approved gene therapy for blindness, according to the Guardian. Twenty-five years of lab work, a married couple who met over a dissected brain, a pair of dogs they treated and then adopted, a patient who saw their child's face for the first time.

None of that trends. None of it moves a share price on Monday. And that is exactly why the prize matters. Luxturna treats a form of inherited retinal dystrophy by delivering a working copy of the RPE65 gene directly into the eye — one dose, lifelong effect. It is the template every other gene therapy has tried to copy since. In a news cycle where "breakthrough" usually means a new chatbot demo, a team that spent a quarter of a century getting a single drug approved feels almost subversive. The lesson is uncomfortable: the innovations that actually change lives rarely arrive on schedule, and rarely fit in a press release.

What does Trump's psychedelic order actually change?

On Saturday, Donald Trump signed an executive order directing the Food and Drug Administration to expedite its review of psychedelic drugs, including ibogaine, the Guardian reports. The framing is veteran-friendly: US military groups have argued that ibogaine can help treat post-traumatic stress disorder, and the political symbolism of a Republican president endorsing psychedelic medicine is, to put it mildly, not what anyone predicted a decade ago.

The substance beneath the symbolism is trickier. Expedited review is not approval. Ibogaine carries known cardiac risks. Rigorous US clinical data remains thin, which is part of why the FDA has moved slowly — and part of why veterans have been travelling to Mexico for treatment. An executive order can accelerate paperwork; it cannot manufacture trial results. The real test will be whether "expedite" means resourcing proper studies or simply leaning on the agency to say yes faster. For a UK audience watching from a regulatory system that tends to trail the FDA by years, the outcome will shape what the MHRA feels obliged to look at next. Psychedelic medicine has quietly become bipartisan. It has not yet become proven.

Are iris scans the new CAPTCHA?

Then there is the other end of the innovation spectrum: the one where the product is you. Tinder and Zoom are rolling out "proof of humanity" eye-scans designed to identify users by their irises and lock out AI-generated fake accounts and scams, the BBC reports. The logic is bleakly tidy. AI has made text, voice and video cheap to fake. Irises, for now, are not. So the dating app and the video call are becoming biometric checkpoints.

It works, right up until you ask the obvious questions. Who stores the iris template, and for how long. What happens when that database leaks — because biometric databases do leak, and you cannot change your eyeballs the way you change a password. Which jurisdictions get the opt-out and which do not. The UK's Information Commissioner's Office has already been wary of biometric creep in workplaces and retail; extending it to consumer dating and video meetings is a different order of intimacy. The deeper point: every new AI capability is now being met with a new demand for bodily data. That is an innovation story too, just not a flattering one.

What to take away

Three stories, three speeds. Gene therapy earns a prize after a quarter-century because it was done properly. Psychedelic medicine gets a political shortcut that may or may not survive contact with evidence. Biometric identity becomes the quiet price of using apps that used to need nothing more than an email.

Innovation is not a single thing moving in a single direction. This week it behaved like three different industries wearing the same hoodie. Watch which of them you are actually being sold.